FORM 8.1(a) & (b) (Opening Position Disclosure)

(a) 

Full name of discloser:

Alkermes plc

(b)

Owner or controller of interests and short

positions disclosed, if different from 1(a):

The naming of nominee or vehicle

companies is insufficient. For a trust, the

trustee(s), settlor and beneficiaries must

be named.

N/A

(c)

Name of offeror/offeree in relation to whose

relevant securities this form relates:

Use a separate form for each offeror/offeree

Avadel

Pharmaceuticals 

plc

(d)

Is the discloser the offeror or the offeree?

OFFEROR

(e) 

Date position held:

The latest practicable date prior to the

disclosure

3 November

2025

(f)  

In addition to the company in 1(c) above, is

the discloser also making disclosures in

respect of any other party to the offer?

If it is a cash offer or possible cash offer, state

"N/A"

N/A

Details of any interests and short positions (including directors'

and other employee options) of any person acting in concert with

the party making the disclosure:

Interests of J.P. Morgan (together with its members of staff under Rule 

3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to

Alkermes plc, but, for clarity, not held on behalf of Alkermes plc:

Party

Class of 

Relevant

Security

Number of 

ordinary

shares held

at midnight

(ET) on

3 November

2025

Percentage 

of total

issued share

capital

(rounded)

55I, LLC

Ordinary 

shares of

US$0.01

each

53

0.0001 %

JPMorgan

Chase Bank,

National

Association

Ordinary 

shares of

US$0.01

each

13,500

0.0139 %

TOTAL

13,553

0.0139 %

Details of any open stock-settled derivative positions (including traded 

options), or agreements to purchase or sell relevant securities, should

be given on a Supplemental Form 8.

Details of any indemnity or option arrangement, or any agreement

or understanding, formal or informal, relating to relevant securities

which may be an inducement to deal or refrain from dealing entered 

into by the party to the offer making the disclosure or any person

acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If

there are no such agreements, arrangements or understandings, state

"none"

None

Full details of any agreement, arrangement or understanding

between the person disclosing and any other person relating to the

voting rights of any relevant securities under any option referred

to on this form or relating to the voting rights or future acquisition

or disposal of any relevant securities to which any derivative

referred to on this form is referenced. If none, this should be stated. 

None

Is a Supplemental Form 8 attached?   

YES/NO

No

Date of disclosure:

5 November 2025

Contact name:

Sandy Coombs, Alkermes

Telephone number:

+1 781 609 6377

Public disclosures under Rule 8.1 of the Rules must be made to a 

Regulatory Information Service.